Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Novartis and Gilead’s multiple myeloma CARs diverge
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.